PERSONAL

CANCER

IMMUNOTHERAPIES

Matching a Cancer Cure

to Patients’ Genetic Code

PREDICTIVE

DIAGNOSTIC TESTS

Predicting Cancer Immunotherapy Responses

DIGITAL PEPTIDE

IMMUNOTHERAPY

DEVELOPMENT

Using proprietary databases of tumors and patients

IN SILICO

HUMAN MODEL

Predicting the Outcome

of Clinical Trials

Treos Bio is a clinical stage company introducing a disruptive computational technology to change the paradigm of cancer immunotherapy development by resolving the dual challenges of patient and tumor heterogeneity. We use proprietary therapeutic peptides, produced through commercially scalable processes without need for tumor biopsy, to stimulate clinically effective cancer-specific immune responses in patients predicted by our diagnostic tests to respond.

Our Products